Filing Flows › Gossamer Bio (GOSS) › Q2 2026 › vs Q1 2026
Gossamer Bio (GOSS) Q2 2026 vs Q1 2026 (quarter over quarter)
Gossamer Bio's revenue fell $7.7M (-46%) from $17.0M in Q1 2026 to $9.2M in Q2 2026.
Gossamer Bio, Q2 2026: revenue $9.2M (-20% year over year), operating margin -282.2%, net earnings $16.9M, operating cash flow −$39.4M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $9.2M | $17.0M | −$7.7M | -46% |
| Other income, net | $43.0M | −$1.8M | $44.8M | — |
| Costs & expenses | $52.2M | $63.6M | −$11.4M | -18% |
| Operating costs | $35.3M | $61.8M | −$26.5M | -43% |
| Net earnings | $16.9M | −$46.7M | $63.6M | — |
| Research & development | $26.4M | $43.1M | −$16.7M | -39% |
| General & admin | $8.9M | $18.7M | −$9.8M | -53% |
| Operating cash sources | $58.8M | −$1.6M | $60.4M | — |
| Share-based compensation | $2.5M | $6.3M | −$3.8M | -61% |
| Cash used in operations | $39.4M | $38.7M | $703K | +2% |
| Working capital & other | $58.8M | −$1.6M | $60.4M | — |
Questions
How much did Gossamer Bio's revenue grow quarter over quarter in Q2 2026?
Gossamer Bio's revenue fell $7.7M (-46%) from $17.0M in Q1 2026 to $9.2M in Q2 2026.